Navigation Links
Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)
Date:8/2/2009

XA manufactured using the proposed commercial manufacturing process. The Company currently expects that it will seek to address this issue by reverting to and revalidating the manufacturing process used to produce KRYSTEXXA for the Phase 3 clinical trials.

The complete response letter also stated that the FDA has determined that a REMS is necessary for KRYSTEXXA consisting of:

  • A Medication Guide to ensure the safe and effective use of KRYSTEXXA by patients,
  • A Communication Plan directed to healthcare providers likely to prescribe KRYSTEXXA to support the dissemination of information about the risks of severe infusion reactions and possible anaphylaxis, the risk of severe adverse reactions in administering KRYSTEXXA to patients with glucose-6-phopshate dehydrogenase (G6PD) deficiency and major cardiovascular events, and
  • An Assessment Plan to monitor and assess the effectiveness of the Medication Guide and Communication Plan in communicating to patients and physicians an understanding of the risks of KRYSTEXXA treatment.

The complete response letter included additional CMC comments focused on tightening manufacturing parameters and narrowing analytical specifications associated with commercial production. The Company was also informed that its resubmission to the FDA in response to the complete response letter must include an update of safety data from all on-going studies. Additionally, the Company's drug substance manufacturer BTG-Israel has already provided a work plan to remediate observations arising from the FDA pre-approval inspection of BTG-Israel's manufacturing facility and a satisfactory inspection report is required prior to the approval of KRYSTEXXA.

"While our timeline for resubmission to the FDA is subject to a number of uncertainties, we currently believe that we can target completion of our resubmission for early 201
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Savient Pharmaceuticals to Present at the Credit Suisse Phoenix Healthcare Conference on November 13th
2. Savients Board of Directors Forms a Board Committee to Oversee the Regulatory and Pre-Launch Activities for Pegloticase
3. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
4. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results
5. Savient Pharmaceuticals to Present at The Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 05, 2015 , ... Renowned review site BestMillionaireDatingSites.com ... the latest update, MillionaireMatch.com has been ranked as the best dating service in the ... for a life companion. It is essential that people find the right dating platform ...
(Date:8/4/2015)... ... 2015 , ... Statement by Paul Gionfriddo, President and CEO, Mental Health America ... Reform Act of 2015 by Senators Bill Cassidy and Christopher Murphy. It ... , “This legislation and H.R. 2646 [The Helping Families in Mental ...
(Date:8/4/2015)... ... August 04, 2015 , ... Exsurco Medical, Inc. ... Tissue Banks (AATB) as an Affiliate Member. Exsurco Medical finds this an ... save and improve lives by promoting the safety, quality and availability of donated ...
(Date:8/4/2015)... ... August 04, 2015 , ... Rhode Island Medical Imaging (RIMI) ... George Washington Medical Building on Wake Robin Road in Lincoln, RI. This satellite ... will offer the most extensive out-patient x-ray hours in the state, which includes evenings ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... to Los Angeles commercial customers. Finding reliable hardware can be difficult and ... When putting an office together or designing a new facility, it is ...
Breaking Medicine News(10 mins):Health News:BestMillionaireDatingSites.com Publishes Reviews of the Best Dating Sites for Wealthy Singles 2Health News:MHA Applauds Introduction of Mental Health Reform Act of 2015 2Health News:MHA Applauds Introduction of Mental Health Reform Act of 2015 3Health News:Exsurco Medical Joins AATB as Affiliate Member 2Health News:Rhode Island Medical Imaging Opens Satellite Imaging Center on Wake Robin Road in Lincoln 2Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 2Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 3Health News:Ryadon, Inc. is Now Offering their Ball Bearing Drawer Slides to Los Angeles, CA Commercial Customers 4
... Symbol: CYT, MONTREAL, May 12 /PRNewswire-FirstCall/ - CryoCath(R) ... cardiac,arrhythmias, today announced financial results for the second quarter,ended ... and Operational Highlights:, - Accelerated revenue ... 37.6% increase over comparable ...
... May 12 Mesa Laboratories,Inc. (Nasdaq: MLAB ... has,declared a regular quarterly cash dividend of ten ... 13, 2008 to shareholders of record at the ... Laboratories develops, acquires, manufactures and markets,electronic instruments and ...
... motor scores, researchers find , , MONDAY, May 12 (HealthDay ... difference for Parkinson,s patients treated with electrodes surgically implanted ... Implanting electrodes to stimulate the subthalamic nucleus, a part ... people with Parkinson,s disease reduce their medication intake by ...
... more likely the younger a child is at diagnosis, study finds, ... percent of people with multiple sclerosis are diagnosed when they,re children, ... causing memory and attention problems, and possibly low IQ scores. ... diagnosis, the more likely he or she is to have a ...
... be even more dangerous than previously thought , , MONDAY, ... tiny, dirty particles in polluted air seems to increase ... clots in the thighs or legs, an Italian study ... myocardial infarction [heart attack] and stroke," said Dr. Andrea ...
... have developed a software toolbox that is intended to help bioscience researchers ... Newberg, a ... and its underlying methods as important for identifying biomarkers that could be ... ...
Cached Medicine News:Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 2Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 3Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 4Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 5Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 6Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 7Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 8Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 9Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 10Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 11Health News:CryoCath Announces Fiscal 2008 Second Quarter Results 12Health News:Electrode Placement Key to Brain Stimulation for Parkinson's Patients 2Health News:Multiple Sclerosis Affects Children's Cognitive Skills 2Health News:Multiple Sclerosis Affects Children's Cognitive Skills 3Health News:Air Pollution Linked to Blood Clots in Legs 2Health News:Air Pollution Linked to Blood Clots in Legs 3Health News:Carnegie Mellon engineering researchers automate analysis of protein patterns 2
(Date:8/4/2015)... Aug. 5, 2015 Karuna Pharmaceuticals, Inc. ... developing a novel product candidate for the treatment ... a Translation Fund Award from the Wellcome Trust ... up to $3.84 million. The funding, along with ... Karuna,s lead program KarXT, a potentially innovative therapy ...
(Date:8/4/2015)... , England , Aug. ... and UK biotechnology company Synairgen plc (LSE: SNG) today announced ... selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) ... IPF affects in the region of 100,000 ... global revenues in excess of $1.1 billion by 2017. The LOXL2 ...
(Date:8/4/2015)... -- On August 3, 2015, a press conference on anti-virus ... donation ceremony of a million masks by Wuhan Longfeixiang Technology ... . Wuhan Longfeixiang Technology ... Hubei Longfeixiang Industrial Group, which has successfully developed the ... anti-pollution mask, filling the global gap for masks of ...
Breaking Medicine Technology:Karuna Receives Wellcome Trust Award to Advance Innovative Clinical Stage Product Candidate for the Treatment of Schizophrenia 2Karuna Receives Wellcome Trust Award to Advance Innovative Clinical Stage Product Candidate for the Treatment of Schizophrenia 3Karuna Receives Wellcome Trust Award to Advance Innovative Clinical Stage Product Candidate for the Treatment of Schizophrenia 4Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis 2Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis 3
...
Strong, 14 gauge steel construction for lasting quality. Locking wheels for use on carpet or tile flooring. Whisper quiet up/down movement. Easy cleaning deluxe laminated top. Three year warranty....
Trial lens set +/- Cyl....
...
Medicine Products: